The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.

Download and Print: Download Printer-friendly PDF Download data

Table 19.29

All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypesa

SEERb 5-Year Relative Survival (Percent) by Age at Diagnosis
All Races, Both Sexes, 2009-2015

Site All Ages Ages 0-19 Ages 20-64 Ages 65+
Count Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval		 Percent 95%
Confidence
Interval
Low High Low High Low High Low High
Lymphoid Neoplasm 184,989 71.3 71.0 71.6 90.5 89.8 91.2 78.6 78.3 78.9 61.7 61.2 62.2
1 Hodgkin Lymphoma 14,589 86.6 85.9 87.3 97.3 96.2 98.0 90.0 89.3 90.7 58.0 55.0 60.9
2 Non-Hodgkin lymphoma 166,396 70.4 70.1 70.7 88.8 88.0 89.6 77.2 76.8 77.5 62.4 61.9 62.9
2(a) Non-Hodgkin lymphoma, B-cell 154,493 70.7 70.4 71.1 89.6 88.7 90.4 77.9 77.5 78.3 62.9 62.4 63.4
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell 8,624 68.9 67.7 70.0 88.9 87.9 89.9 41.9 39.6 44.2 17.8 14.2 21.8
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell 137,350 71.0 70.7 71.4 92.5 90.6 94.0 79.3 78.9 79.7 63.4 62.9 64.0
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma 33,231 81.6 80.8 82.3 93.8 63.0 99.1 88.9 88.1 89.6 76.5 75.4 77.5
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma 29,025 84.5 83.8 85.3 91.7 53.7 98.8 91.8 91.0 92.6 79.6 78.4 80.7
2(a) 2.1.2. Prolymphocytic leukemia, B-cell 90 53.7 39.8 65.8 100.0 - - 63.9 40.2 80.3 43.4 26.0 59.7
2(a) 2.1.3. Mantle-cell lymphoma 4,116 61.1 59.0 63.2 - - - 70.2 67.4 72.8 54.0 50.9 57.0
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglubulinemia 3,069 82.8 80.3 85.1 100.0 - - 89.6 86.6 91.9 78.9 75.2 82.1
2(a) 2.2.1. Lymphoplasmacytic lymphoma 1,363 82.2 78.3 85.4 100.0 - - 85.9 81.2 89.6 79.8 74.2 84.3
2(a) 2.2.2. Waldenstrom macroglubulinemia 1,706 83.4 79.8 86.3 - - - 92.5 88.3 95.2 78.2 73.1 82.5
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL) 35,369 63.2 62.6 63.9 90.8 87.4 93.2 72.8 72.0 73.6 53.7 52.6 54.7
2(a) 2.3.1. DLBCL, NOSc 34,815 62.9 62.3 63.6 90.8 87.3 93.4 72.5 71.7 73.3 53.7 52.6 54.7
2(a) 2.3.2. Intravascular large B-cell lymphoma 69 47.8 34.1 60.3 - - - 52.6 34.1 68.2 42.6 23.2 60.8
2(a) 2.3.3. Primary effusion lymphoma 47 52.4 35.7 66.7 - - - 50.6 32.1 66.5 54.2 18.3 80.2
2(a) 2.3.4. Mediastinal large B-cell lymphoma 438 88.4 84.5 91.4 89.9 71.7 96.7 90.3 86.3 93.2 47.9 24.1 68.3
2(a) 2.4. Burkitt lymphoma/leukemia 2,170 64.1 61.8 66.3 92.8 89.8 95.0 59.8 56.7 62.7 38.9 33.3 44.5
2(a) 2.5. Marginal-zone lymphoma (MZL) 10,080 90.3 89.2 91.3 98.6 90.6 99.8 94.2 93.1 95.1 86.4 84.4 88.2
2(a) 2.5.1. Splenic MZL 850 87.2 82.8 90.6 - - - 90.0 85.0 93.5 85.2 77.8 90.2
2(a) 2.5.2. Extranodal MZL, MALTc type 6,278 93.9 92.5 95.0 98.0 86.3 99.7 95.9 94.6 96.9 91.4 88.7 93.5
2(a) 2.5.3. Nodal MZL 2,952 83.6 81.3 85.7 100.0 - - 91.0 88.5 92.9 77.4 73.5 80.7
2(a) 2.6. Follicular lymphoma 17,590 88.4 87.6 89.2 95.5 82.0 98.9 92.9 92.1 93.6 82.6 81.0 84.1
2(a) 2.7. Hairy-cell leukemia 1,569 94.2 91.7 95.9 - - - 97.0 95.7 97.9 85.6 78.6 90.4
2(a) 2.8. Plasma cell neoplasms 34,254 52.2 51.4 52.9 83.6 48.8 95.6 63.5 62.5 64.5 43.5 42.5 44.5
2(a) 2.8.1. Plasmacytoma 2,009 70.7 67.8 73.4 90.0 47.3 98.5 79.7 76.3 82.6 59.0 53.9 63.7
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia 32,245 51.0 50.2 51.8 50.0 0.6 91.0 62.2 61.1 63.2 42.8 41.7 43.8
2(a) 2.9. Heavy chain disease 18 61.4 28.3 82.8 100.0 - - 83.9 12.0 98.6 29.5 3.6 63.8
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOSc 8,519 68.4 66.9 69.8 91.7 79.4 96.8 78.4 76.6 80.2 61.9 59.8 64.0
2(b) Non-Hodgkin lymphoma, T-cell 11,325 66.1 65.0 67.2 85.6 83.3 87.6 70.2 68.9 71.6 52.2 50.0 54.4
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell 187 65.2 57.6 71.8 91.7 83.3 96.0 48.4 36.6 59.2 - - -
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell 11,122 66.2 65.0 67.2 85.1 82.6 87.2 70.6 69.3 71.9 52.4 50.1 54.6
2(b) 2.1. Mycosis fungoides/Sezary syndrome 2,846 90.9 88.9 92.6 100.0 - - 93.1 91.1 94.6 85.8 80.8 89.6
2(b) 2.1.1. Mycosis fungoides 2,746 92.4 90.5 94.0 100.0 - - 94.1 92.2 95.6 88.2 83.0 91.9
2(b) 2.1.2. Sezary syndrome 100 45.4 31.2 58.5 - - - 46.3 26.5 64.0 45.7 26.9 62.8
2(b) 2.2. Peripheral T-cell lymphoma 5,920 58.4 56.9 60.0 86.9 81.9 90.6 66.5 64.6 68.4 44.1 41.3 46.7
2(b) 2.2.1. Peripheral T-cell lymphoma, NOSc 2,119 40.0 37.5 42.5 64.2 46.6 77.3 49.9 46.6 53.2 27.4 23.8 31.2
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma 780 38.6 34.4 42.8 100.0 - - 48.4 41.9 54.6 31.1 25.6 36.9
2(b) 2.2.3. Subcutaneous panniculitis- like T-cell lymphoma 88 90.3 78.4 95.8 88.4 40.6 98.3 88.0 72.9 95.0 93.7 32.0 99.6
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type 1,110 67.6 64.3 70.7 89.6 83.2 93.6 71.6 67.7 75.2 45.6 37.7 53.1
2(b) 2.2.5. Hepatosplenic T-cell lymphoma 66 32.7 20.0 45.9 66.8 5.3 94.6 31.0 17.4 45.6 - - -
2(b) 2.2.6. Enteropathy-type T-cell lymphoma 69 9.3 3.3 19.3 - - - 10.9 2.8 25.4 7.5 1.4 21.0
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOSc 1,183 84.7 81.3 87.5 100.0 - - 88.8 85.3 91.5 77.1 69.6 82.9
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma 505 88.1 82.7 91.9 91.3 69.3 97.8 91.8 86.5 95.1 81.2 68.5 89.2
2(b) 2.3. Adult T-cell leukemia/lymphoma 1,671 64.1 61.3 66.7 83.2 80.0 85.9 49.6 45.0 54.0 21.6 13.8 30.4
2(b) 2.4. NKc/T-cell lymphoma, nasal-type/ agressive NKc-cell leukemia 466 42.7 37.3 47.9 58.8 32.5 77.8 44.4 38.2 50.4 35.7 24.7 46.8
2(b) 2.5. T-cell large granular lymphocytic leukemia 28 63.8 38.7 80.8 - - - 78.5 43.7 93.1 46.0 14.7 73.1
2(b) 2.6. Prolymphocytic leukemia, T-cell 191 14.7 8.8 22.0 - - - 23.0 13.4 34.2 5.0 1.0 14.4
2(b) 3. Non-Hodgkin lymphoma, NOSc , T-cell 16 44.3 16.7 69.0 - - - 38.8 10.3 67.3 41.4 5.1 77.0
2(c) Non-Hodgkin lymphoma, unknown lineage 578 52.9 48.2 57.4 84.6 74.3 91.0 52.9 46.1 59.1 41.6 33.6 49.3
2(c) 1. Precursor lymphoblastic leukemia/ lymphoma, unknown lineage 194 59.3 51.7 66.2 85.5 75.1 91.7 52.8 39.2 64.7 23.9 12.3 37.6
2(c) 2. Prolymphocytic leukemia, unknown lineage 19 38.4 15.5 61.2 - - - - - - 29.9 8.9 54.7
2(c) 3. Non-Hodgkin lymphoma, NOSc, unknown lineage 365 50.0 43.7 55.9 50.0 0.6 91.0 52.5 44.6 59.8 47.0 37.1 56.3
2(*) 1. Total precursor lymphoma/leukemiad 9,005 68.6 67.5 69.7 88.9 87.9 89.9 42.6 40.3 44.8 18.3 14.8 22.0
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma 290 77.3 70.4 82.8 - - - 83.9 76.3 89.2 65.7 51.3 76.8
4 Lymphoid neoplasm, NOSc 3,714 51.7 49.6 53.7 84.7 76.3 90.4 66.9 64.0 69.5 40.0 37.2 42.8

Footnotes:

a Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

b SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

c NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.